[New post] UOBKH: Innovent Biologics (1801 HK)

alanyeo posted: " 1H21: Revenue Grew 97.3% yoy, Aiming To Maintain Tyvyt In Leading MarketPositionInnovent reported strong revenue growth of 97.3% yoy to Rmb1.9b in 1H21. Adjusted net losses increased 27.1% yoy to Rmb676.9m. The results are overall in line with our estima" Respond to this post by replying above this line New post on Alpha Edge Investing UOBKH: Innovent Biologics (1801 HK) by alanyeo 1H21: Revenue Grew 97.3% yoy, Aiming To Maintain Tyvyt In Leading MarketPositionInnovent reported strong revenue growth of 97.3% yoy to Rmb1.9b in 1H21. Adjusted net losses increased 27.1% yoy to Rmb676.9m. The results are overall in line with our estimates. Innovent saw smooth R&D progress in 1H21. Although Innovent is facing intensifying competition in the […] Read more of this post alanyeo | August 27, 2021 at 3:22 pm | Categories: Equities - Research Reports by Brokers/ Banks | URL: https://wp.me/p7fA1-3ma Comment    See all comments    Like Unsubscribe to no longer receive posts from Alpha Edge Investing. Change your email settings at Manage Subscriptions. Trouble clicking? Copy and paste this URL into your browser: http://alphaedgeinvesting.com/2021/08/27/uobkh-innovent-biologics-1801-hk/ Thanks for flying with WordPress.com